血漿療法市場：依類型、應用、最終用戶和地區劃分 - 全球預測（～2036年）

全球血漿療法市場在預測期（2026-2036年）預計將以 10.4%的年複合成長率成長，從2026年的8.2億美元成長到2036年的約 22.1億美元。本報告對五大主要地區的血漿療法市場進行了詳細分析，重點關注當前市場趨勢、市場規模、近期發展以及至2036年的預測。透過廣泛的二級和一級研究以及對市場現狀的詳細分析，對關鍵產業驅動因素、限制因素、機會和挑戰進行了影響分析。

推動血漿療法市場成長的關鍵因素包括：富血小板血漿（PRP）療法已確立的治療益處、醫療保健專業人員和患者對 PRP 療法的認知度不斷提高、肌肉骨骼和運動損傷的增加以及全球美容手術數量的成長。此外，PRP療法在各個醫學專科領域的應用不斷擴展、PRP製備系統的技術進步以及新興經濟體醫療基礎設施的發展，預計將為血漿療法市場的企業創造巨大的成長機會。

主要市場趨勢

PRP應用擴展到骨科以外：推動血漿療法市場發展的一個關鍵趨勢是PRP的應用範圍已從傳統的骨科和運動醫學擴展到各個醫學專科。皮膚科和美容醫學已成為重要的成長領域，PRP用於毛髮再生、皮膚再生和抗衰老治療。此外，PRP在臨床應用範圍也穩定擴大，包括風濕病學中的關節疾病管理、眼科學中的乾眼症和角膜疾病，以及口腔醫學和口腔外科中的口腔疾病。這些多樣化的應用顯著擴大目標市場，並吸引新的患者群體接受PRP療法。

推進 PRP 製備技術及標準化：另一個主要趨勢是 PRP 製備技術的進步和標準化過程。製造商開發更有效率、更便利的離心系統，以生產血小板濃度和生長因子光譜均達到最佳狀態的、高品質的PRP。標準化工作目的是解決 PR 製備過程中長期存在的差異性問題，這一問題曾阻礙臨床療效和監管審批。改良的製備技術提升 PRP 治療的臨床療效，並促進其在各種臨床環境中的廣泛應用。先進的自動化系統縮短製備時間並提高可重複性。

不斷成長的臨床證據和監管支持：越來越多的臨床證據支持 PRP 在多個治療領域的療效，推動市場擴張。監管機構日益認可 PRP 的治療價值，鼓勵其進入市場並應用於臨床。這種監管的明確性為 PRP 技術開發和臨床研究的投資提供了支持。

市場區隔

依類型

依類型劃分，預計到2026年，純血小板富集血漿（PRP）將佔據全球血漿療法市場最大的佔有率。純 PRP 具有多項關鍵優勢，包括使用風險極低、經廣泛研究證實的臨床療效，以及促進組織、肌腱和骨骼癒合的成熟能力，鞏固了其作為全球醫療機構中最廣泛採用的PRP 製劑的地位。豐富的臨床證據支持其療效，製備過程簡便，且治療效果穩定，使其成為尋求再生醫學解決方案的醫療服務提供者和患者的首選。其在各種臨床應用中的多功能性和良好的安全性將繼續推動市場需求的持續成長。

然而，預計在預測期內，富含白血球的PRP（L-PRP）的年複合成長率將最高。L-PRP在膝關節和髖關節骨關節炎患者中的臨床應用日益廣泛，加之其在某些治療應用中展現出的良好臨床效果，正推動著這一細分市場的成長。 L-PRP增強的抗發炎和免疫調節特性使其在治療慢性發炎和退化性關節疾病方面特別有效。人們對L-PRP在某些臨床情況下卓越療效的認識不斷提高，也促進了其廣泛應用和市場滲透。此外，富血小板纖維蛋白（PRF）和白血球-富血小板纖維蛋白（L-PRF）作為新興細分市場，在口腔外科、牙周治療和先進的再生醫學手術等領域具有特殊的應用前景。

依應用領域劃分

預計到2026年，骨科和創傷科將佔據全球血漿療法市場最大的佔有率。該領域的領先地位源於富血小板血漿（PRP）在治療各種骨科疾病（包括肌腱損傷、韌帶損傷、軟骨退化和骨關節炎）方面成熟且廣泛的應用記錄。強而有力的臨床證據支持PRP在骨科領域的療效，骨科損傷和年齡相關退化性疾病的高發病率，以及人們對微創治療方案日益成長的偏好，都使骨科成為主要的市場區隔。運動醫學專家和骨科醫生積極採用PRP療法，將其作為治療急性損傷和慢性退化性疾病的有效選擇。

然而，預計在預測期內，皮膚科和美容領域的年複合成長率將最高。皮膚和毛髮相關疾病患者數量的增加、大眾美學意識的提高以及微針和富血小板血漿（PRP）聯合療法在美容領域的日益普及，推動該行業的快速成長。 PRP在毛髮再生、皮膚再生、抗衰老治療和痤瘡疤痕修復等方面的應用，顯著擴大了潛在市場。不斷成長的醫美市場和非手術美容療法的普及，為基於PRP的皮膚病治療創造了巨大的機會。此外，PRP在風濕病（用於關節疾病管理）、眼科（用於乾眼症和角膜疾病）以及口腔醫學（用於牙科和口腔外科手術）等領域的應用，也正獲得越來越多的臨床認可和應用。

依最終使用者劃分

預計到2026年，醫院和診所將佔據全球血漿療法市場最大的佔有率。這一領域的領先地位歸因於醫療保健支出的成長、醫療專業人員對PRP療法的認識和處方量的增加，以及這些機構擁有先進的醫療基礎設施和專用設備。醫院和診所是各醫療專科 PRP 療法的主要服務中心，為患者提供經驗豐富的醫生和全面的治療方案。 PRP 療法已融入骨科、皮膚科和其他專科的標準臨床實踐，推動了其持續成長的需求。

儘管目前研究機構的市場佔有率較小，但它們在推進 PRP 的科學研究和臨床應用方面發揮著越來越重要的作用。學術和研究機構進行先進的研發活動，以最佳化 PRP 製備技術、探索新的治療應用並建立實證臨床方案。這些研究有助於 PRP 療法的更廣泛應用和標準化，最終促進市場擴張並提高臨床可靠性。

區域分析

對該行業的詳細區域分析提供了對五大主要區域（北美、歐洲、亞太、拉丁美洲以及中東和非洲）及其主要國家/地區情況的詳細定性和定量見解。預計到2026年，北美將引領全球血漿療法市場，佔據最大的市場佔有率。這一優勢主要歸功於該地區完善的醫療保健基礎設施、先進醫療技術的廣泛應用、對再生醫學的強有力的監管支持以及可觀的醫療保健支出。美國是最大的市場，這得益於許多大型再生醫學公司的存在、廣泛的臨床研發活動以及患者對富血小板血漿（PRP）療法的高度認知和接受度。北美醫療保健專業人員積極地將PRP作為多個專科的標準治療方案。

歐洲是第二大血漿療法市場，這得益於其健全的醫療保健體系、再生醫學方法的日益普及以及越來越多的臨床證據支持PRP的有效性。德國、法國和英國等國家在引進和規範PRP療法方面處於領先地位。該地區對實證醫學和監管合規的重視，促進了市場成長和臨床信譽。

預計亞太地區將在預測期內實現最快的成長。醫療基礎設施的改善、醫療旅遊的興起、醫療支出的增加以及醫護人員和患者對富血小板血漿（PRP）療法的認知度不斷提高，共同推動了這一加速成長。中國、印度、日本和韓國等國的血漿療法市場正經歷快速擴張。醫療體系的完善、可支配收入的增加以及體育運動參與度的提高，都顯著推動了對再生醫學解決方案的需求。拉丁美洲以及中東和非洲地區由於醫療投資的增加和先進療法的日益普及，也展現出新的發展機會。

目錄

第1章 引言

第2章 研究方法

第3章 執行摘要

第4章 市場洞察

• 驅動因素
  • PRP療法的益處
  • PRP療法認知度的提高
  • 肌肉骨骼和運動傷害的增加趨勢
  • 全球美容手術數量的增加
• 限制因素
  • PRP療法的替代方案
  • PRP使用的副作用
• 機會
  • PRP的拓展應用治療
  • 新興經濟體的醫療進展
• 挑戰
  • PRP 使用的嚴格監管框架
• 波特五力分析

第5章 PRP 的適用標準

第6章 血漿療法市場趨勢

第7章 富血小板血漿療法市場：依類型

• 純富血小板血漿
• 富白血球 PRP
• 純富血小板纖維蛋白
• 富白血球和血小板纖維蛋白（L-PRF）

第8章 富血小板血漿療法市場：依應用

• 骨科和創傷科
• 風濕病科
• 皮膚科和整形外科
• 眼科
• 口腔外科和牙科
• 其他應用

第9章 富血小板血漿療法市場：依最終用戶

• 醫院和診所
• 研究機構

第10章 富血小板血漿療法市場：依地區

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他地區歐洲
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲

第11章 競爭格局

• 關鍵成長策略
• 市場佔有率分析
• 主要公司SWOT分析
• 資金和資助評估

第12章 公司簡介

• Arthrex, Inc.
• DePuy Synthes Inc.
• Stryker Corporation
• Zimmer Biomet Holdings, Inc.
• Terumo Corporation
• Regen Lab SA
• EmCyte Corporation
• Exactech Inc.
• Global Stem Cells Group, Inc.
• Celling Biosciences, Inc.
• Dr PRP USA LLC
• Juventix Regenerative Medical LLC
• 其他

第13章 附錄

Plasma Therapy Market by Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology), End User (Hospitals and Clinics, Research Institutes), and Geography - Global Forecast to 2036

According to the research report titled, 'Plasma Therapy Market by Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology), End User (Hospitals and Clinics, Research Institutes), and Geography - Global Forecast to 2036,' the global plasma therapy market is expected to reach approximately USD 2.21 billion by 2036 from USD 0.82 billion in 2026, at a CAGR of 10.4% during the forecast period (2026-2036). The report provides an in-depth analysis of the global plasma therapy market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the plasma therapy market include the well-documented therapeutic advantages of platelet-rich plasma (PRP) treatment, increasing awareness toward PRP therapies among healthcare professionals and patients, the rising prevalence of musculoskeletal and sports injuries, and the growing number of cosmetic procedures worldwide. Additionally, the expanding applications of PRP treatments in various medical specialties, technological advancements in PRP preparation systems, and advancing healthcare infrastructure in emerging economies are expected to create significant growth opportunities for players operating in the plasma therapy market.

Key Market Trends

Expansion of PRP Applications Beyond Orthopedics: A significant trend shaping the plasma therapy market is the expansion of PRP applications beyond traditional orthopedic and sports medicine uses into diverse medical specialties. Dermatology and cosmetology have emerged as major growth areas, with PRP being utilized for hair restoration, skin rejuvenation, and anti-aging treatments. Additionally, PRP applications in rheumatology for joint disease management, ophthalmology for dry eye syndrome and corneal disorders, and stomatology for dental and oral surgical procedures are gaining increasing clinical traction. This diversification of applications is expanding the addressable market significantly and attracting new patient populations to PRP therapy.

Technological Advancements in PRP Preparation and Standardization: Another major trend is the advancement of PRP preparation technologies and efforts toward standardization of PRP formulations. Manufacturers are developing more efficient and user-friendly centrifugation systems that produce consistent, high-quality PRP with optimal platelet concentrations and growth factor profiles. Standardization efforts are addressing the historical challenge of variability in PRP preparation, which has hindered clinical outcomes and regulatory acceptance. Improved preparation techniques are enhancing the clinical efficacy of PRP treatments and facilitating broader adoption across diverse healthcare settings. Advanced automated systems are reducing preparation time and improving reproducibility.

Increasing Clinical Evidence and Regulatory Support: Growing clinical evidence supporting PRP efficacy across multiple therapeutic applications is driving market expansion. Regulatory bodies are increasingly recognizing the therapeutic value of PRP, facilitating market entry and clinical adoption. This regulatory clarity is supporting investment in PRP technology development and clinical research.

Market Segmentation

Based on Type

By type, pure platelet-rich plasma (PRP) is expected to account for the largest share of the global plasma therapy market in 2026. Pure PRP offers several significant advantages that have established it as the most widely adopted PRP formulation across healthcare settings globally. These advantages include minimal risks associated with its use, well-established clinical efficacy supported by extensive research, and its proven ability to accelerate the healing process of tissues, tendons, and bones. The extensive body of clinical evidence supporting pure PRP efficacy, combined with its straightforward preparation process and consistent therapeutic outcomes, have made it the preferred choice for healthcare providers and patients seeking regenerative medicine solutions. Pure PRP's versatility across multiple clinical applications and its favorable safety profile continue to drive sustained market demand.

However, leukocyte-rich PRP (L-PRP) is projected to grow at the fastest CAGR during the forecast period. The increasing clinical adoption of L-PRP in patients suffering from osteoarthritis of the knee and hip joints, combined with positive clinical outcomes in specific therapeutic applications, is driving accelerated growth in this segment. L-PRP's enhanced anti-inflammatory and immunomodulatory properties make it particularly valuable for managing chronic inflammatory conditions and degenerative joint diseases. The growing recognition of L-PRP's superior therapeutic benefits in specific clinical scenarios is contributing to its expanding adoption and market penetration. Additionally, platelet-rich fibrin (PRF) and leukocyte and platelet-rich fibrin (L-PRF) represent emerging segments with specialized applications in oral surgery, periodontal treatment, and advanced regenerative procedures.

Based on Application

By application, orthopedics and traumatology is expected to account for the largest share of the global plasma therapy market in 2026. This segment's dominance is attributed to the well-established and extensively validated use of PRP in treating various orthopedic conditions, including tendon injuries, ligament damage, cartilage degeneration, and osteoarthritis. The strong clinical evidence supporting PRP efficacy in orthopedic applications, the high prevalence of orthopedic injuries and age-related degenerative conditions, and the growing preference for minimally invasive treatment alternatives have established orthopedics as the primary market segment. Sports medicine professionals and orthopedic surgeons have embraced PRP therapy as a valuable therapeutic option for managing acute injuries and chronic degenerative conditions.

The dermatology and cosmetology segment, however, is projected to grow at the fastest CAGR during the forecast period. The rising number of patients with skin and hair-related conditions, growing beauty consciousness among the general population, and increasing adoption of microneedling combined with PRP for cosmetic purposes are driving rapid growth in this segment. PRP applications for hair restoration, skin rejuvenation, anti-aging treatments, and acne scar revision are expanding the addressable market significantly. The expanding aesthetic medicine market and the popularity of non-surgical cosmetic procedures are creating substantial opportunities for PRP-based dermatological treatments. Additionally, PRP applications in rheumatology for joint disease management, ophthalmology for dry eye syndrome and corneal disorders, and stomatology for dental and oral surgical procedures are gaining increasing clinical recognition and adoption.

Based on End User

By end user, hospitals and clinics are expected to account for the largest share of the global plasma therapy market in 2026. This segment's dominance is attributed to increased healthcare spending, growing awareness and prescriptions for PRP treatments among healthcare professionals, and the availability of advanced medical infrastructure and specialized equipment in these settings. Hospitals and clinics serve as primary delivery points for PRP therapies across various medical specialties, offering patients access to experienced practitioners and comprehensive treatment protocols. The integration of PRP therapy into standard clinical practice across orthopedic, dermatological, and other specialty departments is driving sustained demand.

Research institutes, while representing a smaller market segment currently, are playing an increasingly important role in advancing PRP science and clinical applications. Academic and research institutions are conducting advanced research and development activities to optimize PRP preparation techniques, explore new therapeutic applications, and establish evidence-based clinical protocols. This research is contributing to the broader adoption and standardization of PRP therapies, ultimately supporting market expansion and clinical credibility.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America is expected to dominate the global plasma therapy market with the largest market share. This dominance is primarily attributed to the well-established healthcare infrastructure, high adoption of advanced medical technologies, strong regulatory support for regenerative medicine, and significant healthcare spending in the region. The United States represents the largest market, driven by the presence of leading regenerative medicine companies, extensive clinical research and development activities, and high patient awareness and acceptance of PRP therapies. Healthcare professionals in North America have embraced PRP as a standard therapeutic option across multiple specialties.

Europe represents the second-largest market for plasma therapy, driven by strong healthcare systems, increasing adoption of regenerative medicine approaches, and growing clinical evidence supporting PRP efficacy. Countries including Germany, France, and the United Kingdom are at the forefront of PRP therapy adoption and standardization efforts. The region's emphasis on evidence-based medicine and regulatory compliance is supporting market growth and clinical credibility.

Asia-Pacific is projected to witness the fastest growth during the forecast period. This accelerated growth is fueled by advancing healthcare infrastructure, increasing medical tourism, rising healthcare expenditure, and growing awareness of PRP therapies among healthcare professionals and patients. Countries including China, India, Japan, and South Korea are experiencing rapid expansion of plasma therapy markets. The combination of improving healthcare systems, growing disposable incomes, and increasing sports participation is driving substantial demand for regenerative medicine solutions. Latin America and the Middle East & Africa represent emerging market opportunities with growing healthcare investments and increasing adoption of advanced therapeutic approaches.

Key Players

The key players operating in the global plasma therapy market include established medical device manufacturers with strong distribution networks and specialized regenerative medicine companies focused on PRP technology development. The competitive landscape features a diverse range of manufacturers producing PRP preparation systems, centrifuges, and related medical devices. These companies compete based on the quality and consistency of their PRP preparation systems, technological innovation, clinical evidence supporting their products, therapeutic area expertise, and ability to provide comprehensive solutions that meet evolving healthcare provider needs. Market consolidation has characterized the industry, with larger players acquiring specialized PRP technology companies to expand their regenerative medicine portfolios and enhance technological capabilities.

Key Questions Answered in the Report-

• What is the current revenue generated by the plasma therapy market globally?
• At what rate is the global plasma therapy market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global plasma therapy market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of type, application, and end user are expected to create major traction for the service providers in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global plasma therapy market?
• Who are the major players in the global plasma therapy market? What are their specific service offerings in this market?
• What are the recent strategic developments in the global plasma therapy market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Plasma Therapy Market Assessment -- by Type

• Pure Platelet-rich Plasma (PRP)
• Leukocyte-rich PRP (L-PRP)
• Platelet-rich Fibrin (PRF)
• Leukocyte and Platelet-rich Fibrin (L-PRF)

Plasma Therapy Market Assessment -- by Application

• Orthopedics and Traumatology
• Dermatology and Cosmetology
• Rheumatology
• Ophthalmology
• Stomatology and Dental Surgery
• Other Applications

Plasma Therapy Market Assessment -- by End User

• Hospitals and Clinics
• Research Institutes
• Other End Users

Plasma Therapy Market Assessment -- by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Process
• 2.2. Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Assessment
  • 2.3.1. Market Size Estimation
  • 2.3.2. Bottom-Up Approach
  • 2.3.3. Top-Down Approach
  • 2.3.4. Growth Forecast
• 2.4. Market Share Analysis
• 2.5. Assumptions for this Study
• 2.6. Limitations for the Study

3. Executive Summary

4. Market Insights

• 4.1. Drivers
  • 4.1.1. Advantages Offered by PRP Treatment
  • 4.1.2. Increasing Awareness Toward PRP Therapies
  • 4.1.3. Rising Prevalence of Musculoskeletal and Sports Injuries
  • 4.1.4. Growing Number of Cosmetic Procedures Worldwide
• 4.2. Restraints
  • 4.2.1. Availability of Alternatives for PRP Treatment
  • 4.2.2. Side-Effects Associated with the Use of PRP
• 4.3. Opportunities
  • 4.3.1. Increasing Applications of PRP Treatments
  • 4.3.2. Advancing Healthcare in Emerging Economies
• 4.4. Challenges
  • 4.4.1. Stringent Regulatory Framework for the Use of PRP
• 4.5. Porter's Five Forces Analysis
  • 4.5.1. Bargaining Power of Suppliers
  • 4.5.2. Bargaining Power of Buyers
  • 4.5.3. Threat of Substitutes
  • 4.5.4. Threat of New Entrants
  • 4.5.5. Competitive Rivalry

5. PRP Qualification Criteria

6. Plasma Therapy Market Trends

7. Platelet Rich Plasma Therapy Market, by Type

• 7.1. Introduction
• 7.2. Pure Platelet-rich Plasma
• 7.3. Leukocyte-rich PRP
• 7.4. Pure Platelet Rich Fibrin
• 7.5. Leukocyte and Platelet Rich Fibrin (L-PRF)

8. Platelet Rich Plasma Therapy Market, by Application

• 8.1. Introduction
• 8.2. Orthopedics and Traumatology
• 8.3. Rheumatology
• 8.4. Dermatology and Cosmetology
• 8.5. Ophthalmology
• 8.6. Stomatology and Odontology
• 8.7. Other Applications

9. Platelet Rich Plasma Therapy Market, by End User

• 9.1. Introduction
• 9.2. Hospitals and Clinics
• 9.3. Research Institutes

10. Platelet Rich Plasma Therapy Market, by Geography

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. U.S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. Japan
  • 10.4.2. China
  • 10.4.3. India
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
  • 10.5.1. Brazil
  • 10.5.2. Mexico
  • 10.5.3. Argentina
  • 10.5.4. Rest of Latin America
• 10.6. Middle East & Africa

11. Competitive Landscape

• 11.1. Introduction
• 11.2. Key Growth Strategies
• 11.3. Market Share Analysis
• 11.4. Key Players SWOT Analysis
• 11.5. Funding and Grants Assessment

12. Company Profiles

• 12.1. Arthrex, Inc.
• 12.2. DePuy Synthes Inc.
• 12.3. Stryker Corporation
• 12.4. Zimmer Biomet Holdings, Inc.
• 12.5. Terumo Corporation
• 12.6. Regen Lab SA
• 12.7. EmCyte Corporation
• 12.8. Exactech Inc.
• 12.9. Global Stem Cells Group, Inc.
• 12.10. Celling Biosciences, Inc.
• 12.11. Dr PRP USA LLC
• 12.12. Juventix Regenerative Medical LLC
• 12.13. Others

13. Appendix

• 13.1. Questionnaire
• 13.2. Available Customization